VS

Virendr Singhal

Director Director DIN 00801785
DIN 00801785 First appointment Nov 2005 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Nov 2005
Shareholding value β€’β€’β€’β€’ Premium profile

About Virendr Singhal

Data last updated:

Virendr Singhal was a Director at Mediaid Labs Private Limited (2010) and Director at Reticine Pharmaids Limited (2005–2018). The companies operate in Pharma.

DIN 00801785
Primary Designation Director
Industry Pharma
First Appointment 30 Nov 2005

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Mediaid Labs Private Limited U33125CH2010PTC032274
Director11 Jun 20102010Active
Reticine Pharmaids Limited U00304CH2005PLC029266
Director30 Nov 20052005₹4.74 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Mediaid Labs Private Limited
Reticine Pharmaids Limited
Premium access

Shareholding and investment profile for Virendr Singhal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Virendr Singhal

Virendr Singhal was first appointed on 30 Nov 2005 as Director at Reticine Pharmaids Limited. The most recent appointment on record is 11 Jun 2010 at Mediaid Labs Private Limited.

Virendr Singhal held 2 earlier board appointments: Mediaid Labs Private Limited (Director, 11 Jun 2010 to 07 Sep 2010); Reticine Pharmaids Limited (Director, 30 Nov 2005 to 26 Sep 2018).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available